reports
- ABGSC Services Research
- Ali Shemmari
- Petter Nystrøm
Avista Corp. Reports Financial Results for the First Quarter of 2024, ...
Avista Corp. Reports Financial Results for the First Quarter of 2024, Confirms 2024 Earnings Guidance First quarter consolidated earnings per diluted share of $0.91, in line with expectationsConfirms consolidated earnings guidance of $2.36 to $2.56 per diluted share SPOKANE, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2024. Net income and earnings per diluted share for the first quarter of 2024 compared to the first quarter of 2023 are presented in the table below (dollars in thousands, except per-share data)...
Hardman & Co Research on City of London Investment Group (CLIG): Posi...
Hardman & Co Research Hardman & Co Research on City of London Investment Group (CLIG): Positive inflows boost FUM 01-May-2024 / 11:58 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on City of London Investment Group (CLIG): Positive inflows boost FUM City of London has announced its FUM for 3Q’24. It was a positive quarter, with group FUM rising 5.5%, from $9.58bn to $10.10bn. The largest contribution came from a positive market backdrop: all the benchmark indices for CLIM strategies delivered positive returns over the...
Olema Oncology to Participate in Upcoming Investor Conferences in May
Olema Oncology to Participate in Upcoming Investor Conferences in May SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024Date: Tuesday, May 14, 2024, at 4:35 p.m. PTLocation: Encore Hotel in Las Vegas, NVFormat: Presentation H.C. Wainwright 2nd Annual BioC...
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipe...
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Monday, May 6, 2024 at 8:30 a.m. EDT to report financial results for the first quarter 2024 and provide updates on recent progress against key catalysts from the pipeline. To access the conference call, please register . Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minu...
The Chefs’ Warehouse Reports First Quarter 2024 Financial Results
The Chefs’ Warehouse Reports First Quarter 2024 Financial Results RIDGEFIELD, Conn., May 01, 2024 (GLOBE NEWSWIRE) -- The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its first quarter ended March 29, 2024. Financial highlights for the first quarter of 2024: Net sales increased 21.5% to $874.5 million for the first quarter of 2024 from $719.6 million for the first quarter of 2023.GAAP net income was $1.9 million, or $0.05 per dilu...
Apellis Announces 11 Oral Presentations at the Association for Researc...
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degene...
PolyPid to Participate in Citizens JMP Life Sciences Conference
PolyPid to Participate in Citizens JMP Life Sciences Conference PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024. Citizens JMP Life Sciences Conference PresentationDate: Monday, May 13, 2024Time:2:30 PM ET The PolyPid management team will participate in one-on-one investor meetings during this event. In...
Balchem Corporation to Attend the BMO 19th Annual Global Farm to Marke...
Balchem Corporation to Attend the BMO 19th Annual Global Farm to Market Conference on May 16, 2024 MONTVALE, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the BMO 19th Annual Global Farm to Market Conference on May 16, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will attend the conference. About Balchem Corporation Balch...
ScottsMiracle-Gro Reports Second Quarter Results
ScottsMiracle-Gro Reports Second Quarter Results Strong first half 2024 execution has Company on pace for full-year targetsU.S. Consumer second quarter net sales of $1.38B equal record highQ2 2024 GAAP gross margin of 30.4% and non-GAAP adjusted gross margin of 35.3% reflect 350 and 60 basis point improvements, respectivelyStrong free cash flow delivers net leverage of 6.95x, well below covenant maximumQ2 2024 GAAP EPS of $2.74; non-GAAP Adjusted EPS of $3.69 are ahead of planTeams driving consumer engagement in Q3 representing 60 percent of seasonal POS MARYSVILLE, Ohio, May 01, 2024 (G...
TG Therapeutics Provides Business Update and Reports First Quarter 202...
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan...
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and I...
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables rev...
The Vita Coco Company Reports First Quarter 2024 Financial Results
The Vita Coco Company Reports First Quarter 2024 Financial Results First Quarter Net Sales Increased 2% to $112 million With Vita Coco Coconut Water Growth of 1% First Quarter Net Income Increased $8 million to $14 million and First Quarter Non-GAAP Adjusted EBITDA1 Increased $12 million to $21 million Company raises full year guidance. Expects Net Revenue between $500-$510 million and Adjusted EBITDA2 between $76-$82 million NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform o...
Chimerix Reports First Quarter 2024 Financial Results and Provides Ope...
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update – Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C...
Amicus Therapeutics to Announce First Quarter 2024 Financial Results o...
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A li...
European Wax Center, Inc. to Report First Quarter Fiscal Year 2024 Fin...
European Wax Center, Inc. to Report First Quarter Fiscal Year 2024 Financial Results on May 15th PLANO, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- European Wax Center, Inc. (NASDAQ: EWCZ), the largest and fastest-growing franchisor and operator of out-of-home waxing services in the United States, today announced that it plans to report first quarter fiscal year 2024 financial results before the market opens on Wednesday, May 15, 2024. Following the release, the company’s management will host a conference call at 8:00 a.m. ET/7:00 a.m. CT to review the results. To access the conference call ...
Springbig Applauds DEA’s Recent Reclassification of Marijuana
Springbig Applauds DEA’s Recent Reclassification of Marijuana DEA's Reclassification of Marijuana Boosts Business Opportunities and Consumer Access, Signaling a New Era for the Cannabis Industry BOCA RATON, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Springbig, a leading provider of marketing solutions for the cannabis industry, expressed their strong support for the Drug Enforcement Administration's (DEA) decision to reclassify marijuana as a lower-risk drug, announced yesterday. Reflecting the broad societal trends in the last decade-plus, this move from the DEA proves that the federal gov...
OneWater Marine Inc. Completes the Acquisition of Garden State Yacht S...
OneWater Marine Inc. Completes the Acquisition of Garden State Yacht Sales Acquisition strengthens presence in the Mid-Atlantic U.S. BUFORD, Ga., May 01, 2024 (GLOBE NEWSWIRE) -- OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) announced today that it has completed the previously announced acquisition of Garden State Yacht Sales (“Garden State”), which further expands the Company’s presence in the Mid-Atlantic U.S. and enhances new and pre-owned boat sales, finance, and parts and services offerings. “We would like to thank the Stavola family for the tremendous opportun...
Bombardier fournit des détails sur la commande ferme passée en décembr...
Bombardier fournit des détails sur la commande ferme passée en décembre 2023 par le client NetJets pour 12 avions Challenger 3500 et 232 options NetJets, précieux client de longue date de Bombardier, a été dévoilé comme étant le client qui a passé cette commande ferme en décembre. La commande ferme pour 12 avions d’affaires Challenger 3500 était estimée à 326,4 millions $ US aux prix courants au moment de sa signatureSi toutes les 232 options étaient exercées au fil du temps, la transaction pourrait valoir plus de 6 milliards $ US aux prix courantsCette commande réaffirme les solides liens ...
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chi...
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today annou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.